TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15803071
Drug: 10 station
Normalized name: Brevibacterium stationis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 station exercise class (aerobic exercises, spinal stabilization exercises, and manual therapy, 8 treatments over 8 weeks)
Study: 12480510
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment with standard needles at acupoint LI11 for 30 min
Study: 12480510
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with placebo needles at acupoint LI11 for 30 min
Study: 2289222
Drug: beta‐cyclodextrin‐piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐cyclodextrin‐piroxicam (20 mg daily for eight weeks)
Study: 2289222
Drug: tenoxicam (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenoxicam (dosage not specified, for eight weeks)
Study: 7002483
Drug: Rociverine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rociverine (10 or 20 mg given intravenously)
Study: 7002483
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (20 or 40 mg given intravenously)
Study: 23429925
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral glucosamine sulphate)
Study: 17522506
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b 10 MIU/m (IFN-I group) thrice weekly for 16 weeks
Study: 16838645
Drug: Adjuvant interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant interferon therapy
Study: 15221054
Drug: UDC +
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDC + CDC (125 mg urso-/chenodeoxycholic acid per 25 kg body weight)
Study: 15221054
Drug: M +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: M + UDC + CDC (62.5 mg UDC/CDC plus 125 mg menthol per 25 kg body weight)
Study: 12063630
Drug: Fusafungine in
Normalized name: fusafungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusafungine in spray 4 times daily
Study: 12063630
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard postoperative therapy)
Study: 12063630
Drug: Fusafungine in
Normalized name: fusafungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusafungine in spray
Study: 7855226
Drug: Pindolol, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol, 30 mg orally
Study: 7855226
Drug: L-5-HTP, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-HTP, 200 mg PO
Study: 998549
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of pyridoxine supplementation
Study: 998549
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of pyridoxine supplementation
Study: 998549
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of pyridoxine supplementation
Study: 23676940
Drug: SCIT combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIT combined with standardized treatment for asthma
Study: 23676940
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment alone
Study: 9578250
Drug: Patient-controlled propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-controlled propofol administration
Study: 9578250
Drug: Operator-controlled propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Operator-controlled propofol administration
Study: 7715982
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza A reassortant virus vaccine (10^5 or 10^6 TCID50) administered separately from routine immunizations
Study: 7715982
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza A reassortant virus vaccine (10^6 TCID50) administered with routine immunizations at 2 and 4 months of age
Study: 7715982
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza A reassortant virus vaccine (10^6 TCID50) administered with routine immunizations at 2 and 6 months of age
Study: 23443221
Drug: Rhodiola rosea
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea (3 mg·kg(‐1))
Study: 15531698
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg elemental Fe as (57)Fe-labeled sprinkles added to maize-based porridge
Study: 15531698
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg elemental Fe as (57)Fe-labeled sprinkles added to maize-based porridge
Study: 15531698
Drug: (58)Fe tracer
Normalized name: Fe
DrugBank: Ferric cation (DB13949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (58)Fe tracer (0.2 mg as ferrous citrate) infused intravenously
Study: 11061523
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) infusion at 1, 2, or 4 mIU/min for 10 hours
Study: 11061523
Drug: Dexamethasone (dex;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (dex; 4 mg, iv) followed by OT infusion at 1 mIU/min
Study: 11061523
Drug: Dexamethasone (dex;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (dex; 4 mg, iv) followed by OT infusion at 2 or 4 mIU/min
Study: 11061523
Drug: Dexamethasone (dex;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (dex; 4 mg, iv) in obese subjects
Study: 11061523
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) infusion at 1, 2, or 4 mIU/min in obese subjects
Study: 11061523
Drug: Dexamethasone (dex;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (dex; 4 mg, iv) with OT infusion in obese subjects
Study: 9117220
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment (placebo-like)
Study: 10565580
Drug: High-information preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-information preparation condition
Study: 10565580
Drug: Low-information preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-information preparation condition
Study: 2439799
Drug: Bisoprolol (BPL)
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol (BPL) 20 mg
Study: 2439799
Drug: Atenolol (ATL)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (ATL) 100 mg
Study: 2701823
Drug: EMG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG biofeedback treatment
Study: 2701823
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (routine physiotherapy)
Study: 31164168
Drug: Daily electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily electronic patient-reported outcome (PRO) diaries
Study: 21423758
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 µg/kg BW)
Study: 17490568
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid resuscitation (250 ml bolus every 15 minutes until ITBVI>850 ml/m(2))
Study: 2688147
Drug: 200‐mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg of enoxacin twice a day for two days
Study: 2688147
Drug: 400‐mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐mg of enoxacin twice a day for two days
Study: 29282152
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (50% maximum inspiratory pressure, twice daily for 4 weeks)
Study: 17109337
Drug: AIDSVAX B/E
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX B/E (VaxGen) vaccine
Study: 15009462
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine load
Study: 7848545
Drug: Intra-articular glucocorticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticosteroid therapy
Study: 7848545
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids and corticotrophin (adrenocorticotrophic hormone)
Study: 7848545
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose colchicine
Study: 7848545
Drug: Uricosuric agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uricosuric agents (e.g., probenecid)
Study: 3273865
Drug: Cefadroxil 30
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil 30 mg/kg every 24 hours orally for ten days
Study: 3273865
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V potassium 15 mg/kg every eight hours orally for ten days
Study: 25166440
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I periodontal treatment + NSAID (20 mg tenoxicam tablet once daily for 10 days)
Study: 25166440
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I periodontal treatment + placebo
Study: 19660009
Drug: NVP 200
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 200 mg b.i.d. plus > or =2 NRTIs and DRV/r 300/100 mg b.i.d.
Study: 19660009
Drug: NVP 200
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 200 mg b.i.d. plus > or =2 NRTIs and DRV/r 400/100 mg b.i.d.
Study: 19660009
Drug: NVP 200
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 200 mg b.i.d. plus > or =2 NRTIs
Study: 9626901
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of Mg orally per day for 1 month
Study: 9626901
Drug: No Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Mg (control group)
Study: 7833230
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg day-1)
Study: 3046631
Drug: Dilevalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (100 mg to 800 mg)
Study: 30795811
Drug: Multi-component smoking
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component smoking cessation service package (regular motivation by nurse, monthly piCO+ Smokerlyzer test, assistance from trained family member, optional nicotine replacement gum)
Study: 20868965
Drug: Remifentanil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (4 μg/kg IV)
Study: 18441042
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes of daily training in sit‐to‐stand and leg strengthening exercises for 30 minutes, on weekdays for two weeks, with a physiotherapy assistant
Study: 18441042
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received arm therapy
Study: 18441042
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes of daily training in sit‐to‐stand
Study: 15876493
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic solution with morphine (1 mg)
Study: 15876493
Drug: Standard local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard local anaesthetic solution (articaine plus epinephrine)
Study: 10371919
Drug: One randomly
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One randomly selected implant per patient
Study: 10371919
Drug: Entire material
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entire material of 1,738 implants
Study: 8676228
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg/kg) alone
Study: 8676228
Drug: Midazolam (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.35 mg/kg) and ketamine (5 mg/kg)
Study: 3963025
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg per day
Study: 3067924
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg per day
Study: 3963025
Drug: Flurbiprofen 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 200 mg per day
Study: 3963025
Drug: Aspirin 2600
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 2600 mg per day
Study: 3963025
Drug: Flurbiprofen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (all doses)
Study: 31634871
Drug: Dexmedetomidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (25 mg slowly injected before surgery)
Study: 25318186
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of pegaptanib sodium
Study: 22458638
Drug: Active pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active pindolol 20 mg retard daily
Study: 15625220
Drug: Treatment Initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Initiation Program (TIP)
Study: 15625220
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (pharmacotherapy alone)
Study: 2911999
Drug: Sodium phytate
Normalized name: sodium phytate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phytate (2 mg)
Study: 2911999
Drug: Sodium phytate
Normalized name: sodium phytate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phytate (25 mg)
Study: 2911999
Drug: Sodium phytate
Normalized name: sodium phytate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phytate (250 mg)
Study: 31347612
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lanadelumab every 2 weeks
Study: 27989681
Drug: Catheter ablation
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter ablation (CA) plus antiarrhythmic drugs
Study: 27989681
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs alone (control group)
Study: 21562066
Drug: Traditional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional and non-traditional risk markers (IL‐1β, IL‐6, TNF‐α, hsCRP, interferon gamma, leptin, IGF‐I, insulin, proinsulin, NT‐proBNP)
Study: 17236635
Drug: Desflurane/N2O/fentanyl anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desflurane/N2O/fentanyl anesthesia with rocuronium 0.6 mg/kg
Study: 17236635
Drug: Propofol/N2O/fentanyl anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/N2O/fentanyl anesthesia with rocuronium 0.6 mg/kg
Study: 12851747
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg 17beta‐estradiol implant
Study: 9076645
Drug: Placebo implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implant
Study: 8400558
Drug: Mn-DPDP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mn-DPDP at a concentration of 50 mumol/mL
Study: 8400558
Drug: Mn-DPDP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mn-DPDP at a concentration of 10 mumol/mL
Study: 3511308
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of metoprolol once daily
Study: 3511308
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of hydrochlorothiazide once daily
Study: 24327175
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 2 × 2 mg for five consecutive days
Study: 12186198
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of 2 x 60 mg iron (one tablet each Friday morning and evening)
Study: 12186198
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1 x 60 mg iron
Study: 1927616
Drug: Nimodipine IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine IV, 2 mg per hour for up to 7 days
Study: 7011688
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g aspirin
Study: 7011688
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg azapropazone
Study: 7011688
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and azapropazone together
Study: 17717604
Drug: Inhaled NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled NO (iNO; 80 ppm)
Study: 15479686
Drug: Alicaforsen enema
Normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicaforsen enema (4 mg/ml)
Study: 15479686
Drug: Alicaforsen enema
Normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicaforsen enema (2 mg/ml)
Study: 9311956
Drug: Naturally occurring
Normalized name: Naturally occurring alkaloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturally occurring beta-carotene (BC) derived from Dunaliella bardawil (64 mg tBC, 69 mg 9cBC)
Study: 27684632
Drug: Warm water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm water intake (200 ml at 98.6°F/37°C in the fourth postoperative hour)
Study: 23999999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the miRNA signature and TNM stage.
Study: 17206944
Drug: Alpha-tocopherol 600
Normalized name: (+)-alpha-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol 600 IU/day plus ascorbic acid 500 mg/day (group B)
Study: 8909662
Drug: i.v. prochlorperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. prochlorperazine 0.1 mg.kg‐1
Study: 8909662
Drug: i.m. prochlorperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. prochlorperazine 0.2 mg.kg‐1
Study: 8909662
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron 0.06 mg.kg‐1
Study: 31434094
Drug: Interventional AVM
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional AVM treatment (surgical resection, endovascular therapy, stereotactic radiosurgery)
Study: 29574974
Drug: Everolimus 2.25-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2.25-3 mg BID in transplant patients
Study: 29574974
Drug: Everolimus 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3.75 mg BID for oncological indications
Study: 24478323
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (sensorimotor, endurance, and strength training twice a week for 36 weeks)
Study: 19171009
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more doses of sulfadoxine-pyrimethamine (SP)
Study: 19171009
Drug: Each increment
Normalized name: Urinary concrement solvents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each increment in number of SP doses
Study: 17573796
Drug: 32 tablets
Normalized name: phosphorus 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 tablets (48 g) of sodium phosphate (NaP)
Study: 17573796
Drug: 2L polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L polyethylene glycol (PEG) solution plus 4 (20 mg) bisacodyl tablets
Study: 15833091
Drug: Topiramate 200
Normalized name: topiramate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 200 mg per day
Study: 15833091
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg per day)
Study: 15833091
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 or 200 mg per day)
Study: 11812917
Drug: Epoetin alfa,
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa, 150-300 IU/kg or 10,000-20,000 IU, three times weekly
Study: 11812917
Drug: Epoetin alfa,
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa, once-weekly dosing
Study: 2520419
Drug: Pulsed infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed infrared laser treatment, 12 sessions on alternate days, total energy dose of 5 J each, targeting four painful muscular trigger points and five acupuncture points.
Study: 2520419
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, 12 sessions on alternate days, identical procedure to the intervention group but with nonoperational laser apparatus.
Study: 1036663
Drug: Diets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diets containing proteins (3.0 g of N from rice plus 3.0 g of N from milk)
Study: 1036663
Drug: Diets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diets containing proteins (3.0 g of N from rice plus 3.0 g of N from wheat flour)
Study: 19128713
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 10 mg/mL ropivacaine hydrochloride with epinephrine (n=19)
Study: 19128713
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2.5 mg/mL bupivacaine with epinephrine (n=20)
Study: 16501426
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (80 mg/day)
Study: 16501426
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus heparin (80 mg/day + 5000 IU unfractionated heparin subcutaneously 12 hourly)
Study: 12871893
Drug: Post-menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-menopausal hormone therapy (pHT) regimens including any estrogen, any estrogen plus any progestin, or tibolone
Study: 12871893
Drug: Any estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any estrogen compound